Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
- Written by PR Newswire
NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the combination of an NTRK gene containing a kinase domain and its fusion partner gene. To date, more than 229 fusion partner genes have been...
